Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ALPG | P10696 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16446063 | 0.90 | AAK1 (0.39) | AAK1SMN1; SMN2HPGDALDH1A1CYP1A2 | |
| SCHEMBL11117263 | 0.81 | ALDH1A1 (0.38) | AAK1SMN1; SMN2HPGDALDH1A1CYP1A2 | |
| SCHEMBL11129929 | 0.78 | NR4A2 (0.41) | AAK1SMN1; SMN2HPGDALDH1A1CYP1A2 | |
| SCHEMBL16446124 | 0.78 | TSHR (0.36) | AAK1SMN1; SMN2HPGDALDH1A1CYP1A2 | |
| SCHEMBL28169241 | 0.76 | TSHR (0.35) | AAK1SMN1; SMN2HPGDALDH1A1CYP1A2 | |
| SCHEMBL26696020 | 0.76 | AAK1 (0.41) | AAK1SMN1; SMN2HPGDALDH1A1CYP1A2 | |
| SCHEMBL11112239 | 0.76 | POLB (0.37) | AAK1SMN1; SMN2ALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL16075175 | 0.76 | MDM2 (0.41) | SMN1; SMN2HPGDALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL1668920 | 0.73 | LMNA (0.41) | SMN1; SMN2HPGDALDH1A1LMNAALPG | |
| SCHEMBL2617314 | 0.71 | CTSC (0.40) | CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3030562-B1 | SUBSTITUTED PYRAZOLO[1,5-A]-PYRIDINE-3-CARBOXAMIDES AND USE THEREOF | Bayer Pharma AG (DE) | 2017-07-26 | — | — | EP | disclosed |
| EP-3030562-B1 | SUBSTITUTED PYRAZOLO[1,5-A]-PYRIDINE-3-CARBOXAMIDES AND USE THEREOF | Bayer Pharma AG (DE) | 2017-07-26 | — | — | EP | disclosed |
| US-20170101407-A1 | 6-CHLORINE-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE CARBOXAMIDES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE STIMULATORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-13 | — | — | US | disclosed |
| US-20170101407-A1 | 6-CHLORINE-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE CARBOXAMIDES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE STIMULATORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-13 | — | — | US | disclosed |
| US-20170101407-A1 | 6-CHLORINE-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE CARBOXAMIDES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE STIMULATORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-13 | — | — | US | disclosed |
| EP-3137465-A1 | 6-CHLORINE-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE CARBOXAMIDES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE STIMULATORS | Bayer Pharma Aktiengesellschaft (DE) | 2017-03-08 | — | — | EP | disclosed |
| EP-3137463-A1 | ENANTIOMERS OF THE N-(2-AMINO-5-FLUORO-2-METHYLPENTYL)-8-[(2,6-DIFLUOROBENZYL)OXY]-2-METHYLIMIDAZO[1,2-A]PYRIDINE-3-CARBOXAMIDE, AS WELL AS OF THE DI- AND TRIFLUORO DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-03-08 | — | — | EP | disclosed |
| US-20170057958-A1 | ENANTIOMERS OF THE N-(2-AMINO-5-FLUORO-2-METHYLPENTYL)-8-[(2,6-DIFLUOROBENZYL)OXY]-2-METHYLIMIDAZO[1,2-A]PYRIDINE-3-CARBOXAMIDE, AS WELL AS OF THE DI- AND TRIFLUORO DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-03-02 | — | — | US | disclosed |
| US-20170057958-A1 | ENANTIOMERS OF THE N-(2-AMINO-5-FLUORO-2-METHYLPENTYL)-8-[(2,6-DIFLUOROBENZYL)OXY]-2-METHYLIMIDAZO[1,2-A]PYRIDINE-3-CARBOXAMIDE, AS WELL AS OF THE DI- AND TRIFLUORO DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-03-02 | — | — | US | disclosed |
| US-20170057958-A1 | ENANTIOMERS OF THE N-(2-AMINO-5-FLUORO-2-METHYLPENTYL)-8-[(2,6-DIFLUOROBENZYL)OXY]-2-METHYLIMIDAZO[1,2-A]PYRIDINE-3-CARBOXAMIDE, AS WELL AS OF THE DI- AND TRIFLUORO DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-03-02 | — | — | US | disclosed |
| EP-3030562-A1 | SUBSTITUTED PYRAZOLO[1,5-A]-PYRIDINE-3-CARBOXAMIDES AND USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2016-06-15 | — | — | EP | disclosed |
| EP-3030564-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRAZINECARBOXAMIDES AND USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2016-06-15 | — | — | EP | disclosed |
| WO-2015165970-A1 | 6-CHLORINE-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE CARBOXAMIDES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE STIMULATORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-11-05 | — | — | WO | disclosed |
| WO-2015165930-A1 | ENANTIOMERS OF THE N-(2-AMINO-5-FLUORO-2-METHYLPENTYL)-8-[(2,6-DIFLUOROBENZYL)OXY]-2-METHYLIMIDAZO[1,2-A]PYRIDINE-3-CARBOXAMIDE, AS WELL AS OF THE DI- AND TRIFLUORO DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-11-05 | — | — | WO | disclosed |
| WO-2015165930-A1 | ENANTIOMERS OF THE N-(2-AMINO-5-FLUORO-2-METHYLPENTYL)-8-[(2,6-DIFLUOROBENZYL)OXY]-2-METHYLIMIDAZO[1,2-A]PYRIDINE-3-CARBOXAMIDE, AS WELL AS OF THE DI- AND TRIFLUORO DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-11-05 | — | — | WO | disclosed |
| WO-2015165970-A1 | 6-CHLORINE-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE CARBOXAMIDES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE STIMULATORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-11-05 | — | — | WO | disclosed |
| WO-2015018808-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRAZINECARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-02-12 | — | — | WO | disclosed |
| WO-2015018814-A1 | SUBSTITUTED PYRAZOLO[1,5-A]-PYRIDINE-3-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-02-12 | — | — | WO | disclosed |
| WO-2015018814-A1 | SUBSTITUTED PYRAZOLO[1,5-A]-PYRIDINE-3-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-02-12 | — | — | WO | disclosed |
| WO-2015018808-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRAZINECARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170057958-A1 | ENANTIOMERS OF THE N-(2-AMINO-5-FLUORO-2-METHYLPENTYL)-8-[(2,6-DIFLUOROBENZYL)OXY]-2-METHYLIMIDAZO[1,2-A]PYRIDINE-3-CARBOXAMIDE, AS WELL AS OF THE DI- AND TRIFLUORO DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | AADAC, TNNT2, TNNI3 | AAK1 2689/4885SMN1; SMN2 1771/4885HPGD 563/4885 |
| US-20170101407-A1 | 6-CHLORINE-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE CARBOXAMIDES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE STIMULATORS | GUCY1A2, GUCY1B2, GUCY1A1 | AAK1 1694/4885SMN1; SMN2 2448/4885HPGD 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.